- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07939854
Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage
A Multicenter, Randomized, Open-Label, Blinded-Endpoint Clinical Trial of Neuronavigation-Guided Stereotactic Aspiration Combined With Tenecteplase for Acute Brainstem Hemorrhage
This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Yong Cao
- 전화번호: +86 13601362306
- 이메일: caoyong@bjth.org
연구 장소
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100070
- 모병
- Beijing Tiantan Hospital, Capital Medical University
-
연락하다:
- Yong Cao
- 전화번호: +86 13601362306
- 이메일: caoyong@bjth.org
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years and <80 years.
- Diagnostic CT completed within 24 hours after symptom onset. Patients with unknown onset time will be excluded. For patients with symptoms first noted during sleep, the time last known well will be considered the onset time.
- Acute primary brainstem hemorrhage confirmed by head CT, with the predominant hematoma location in the pons (>50% of the hematoma located in the pons); hematoma volume 5-10 mL as measured by the ABC/2 method. The hematoma must be located within the brainstem parenchyma rather than primarily within the ventricles, although extension into the third or fourth ventricle is permitted. For unilateral hemorrhage, a hematoma volume of 3-5 mL is permitted.
- A repeat CT scan performed 6 hours after symptom onset confirms that the hematoma volume remains within the eligibility range.
- Glasgow Coma Scale (GCS) score ≥5 and <12 at enrollment.
- Randomization initiated between 6 and 12 hours after the diagnostic CT.
- Systolic blood pressure (SBP) <180 mmHg maintained during the 6 hours immediately before randomization.
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Voluntary participation in the study with written informed consent provided by the participant or legally authorized representative, as applicable.
Exclusion Criteria:
- Supratentorial hemorrhage, posterior fossa hemorrhage, or cerebellar hemorrhage.
- Signs of extremely severe disease, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, or loss of spontaneous respiration.
- The predominant portion of the hematoma involves the midbrain or medulla.
- Brainstem hemorrhage secondary to another cerebrovascular or neurological disorder, including cerebral vascular malformation, intracranial aneurysm, other cerebrovascular abnormalities, moyamoya disease, hemorrhagic transformation of ischemic stroke, or hemorrhage related to a neurological tumor.
- Unstable infratentorial space-occupying lesion, transtentorial herniation, or foramen magnum herniation.
- Previous history of brainstem hemorrhage.
- Irreversible brainstem dysfunction, defined as a GCS score ≤4 or ≥12.
- An indication for craniotomy because of either: (a) progressive deterioration of consciousness; or (b) preoperative cerebral herniation, including signs associated with foramen magnum herniation or uncal herniation.
- CT evidence indicating a high risk of rebleeding, including a spot sign.
- Platelet count <100,000/mL or international normalized ratio (INR) >1.4.
- Any irreversible coagulation disorder, including hemophilia or von Willebrand disease, use of anticoagulants such as warfarin, or a known disorder of clot formation, including a hypercoagulable state.
- Inability to maintain INR ≤1.4 despite treatment with short- or long-acting hemostatic agents, including recombinant factor VIIa, fresh frozen plasma, or vitamin K.
- Requirement for long-term anticoagulation. Patients who can undergo temporary reversal of anticoagulation but cannot discontinue warfarin or other anticoagulants for the subsequent 30 days will be excluded.
- Use within 1 week before symptom onset of dabigatran, apixaban, rivaroxaban, tirofiban, ticagrelor, cilostazol, or clopidogrel.
- Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary systems, or respiratory tract bleeding.
- Superficial bleeding at a vascular access site (e.g., venous cutdown or arterial puncture) or surgical site.
- Positive urine or serum pregnancy test in a premenopausal woman without documented surgical sterilization.
- Known hypersensitivity to tenecteplase.
- Previous participation in this study with completed randomization.
- Concurrent participation in another interventional medical study or clinical trial. Participation in an observational study, natural history study, or epidemiological study without an interventional component is permitted.
- Before randomization, the participant is not expected to survive through the Day 365 follow-up, or has requested do-not-resuscitate (DNR) or do-not-intubate (DNI) status.
- Any serious concomitant disease expected to substantially affect prognosis, including severe hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune, or hematologic disease.
- Presence of a mechanical prosthetic heart valve. A bioprosthetic heart valve is permitted.
- Known embolic risk, including a history of left-sided intracardiac thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
- Any condition requiring immediate emergency treatment outside the study protocol, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, loss of spontaneous respiration, signs of cerebral herniation, progressive respiratory or circulatory failure, or a multidisciplinary determination that immediate craniotomy for hematoma evacuation, decompressive craniectomy, emergency external ventricular drainage, or other emergency treatment is required. Study screening and randomization must not delay necessary emergency treatment.
- The participant requests conservative treatment or conventional open microsurgical treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Stereotactic Aspiration Combined With Tenecteplase
Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment. |
Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization. Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.
다른 이름들:
Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation. |
|
활성 비교기: Standard Medical Treatment
|
Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants With GCS Score >8
기간: 90 days after randomization
|
Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. |
90 days after randomization
|
|
All-Cause Mortality
기간: Within 30 days after randomization.
|
Proportion of participants who die from any cause within 30 days after randomization. |
Within 30 days after randomization.
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
7-Day All-Cause Mortality
기간: Within 7 days
|
Within 7 days
|
|
Symptomatic Rebleeding
기간: Within 72 hours after tenecteplase administration
|
Within 72 hours after tenecteplase administration
|
|
Intracranial Bacterial Infection
기간: Within 30 days
|
Within 30 days
|
|
Serious Adverse Events (SAEs)
기간: Within 30 days
|
Within 30 days
|
|
Adverse Events (AEs)
기간: Within 30 days
|
Within 30 days
|
|
Serious Adverse Events (SAEs)
기간: Within 365 days
|
Within 365 days
|
|
Adverse Events (AEs)
기간: Within 365 days
|
Within 365 days
|
|
Proportion With GCS Increase ≥3 Points
기간: 30 days
|
30 days
|
|
Proportion With Recovery of Consciousness
기간: 30 days
|
30 days
|
|
Proportion With mRS 0-3
기간: 90 days
|
90 days
|
|
Proportion With mRS 0-3
기간: 365 days
|
365 days
|
|
Change in GCS Score Over Time
기간: From baseline through 90 days after randomization
|
From baseline through 90 days after randomization
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- LX-2026-0001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .